Clinical Trial

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 28, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-12.
Trial Details
NCT Number NCT06180174
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: Peking University Cancer Hospital & Institute
Conditions B Cell Lymphoma, Non Hodgkin Lymphoma
Enrollment 24 participants
Start Date 2023-12-31
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-28